Gagan Sharma designated as senior management person

Management Changes View source PDF Explain this filing

NOVARTIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹1792.00

prior close

₹1821.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector+2.0%+0.8% vs sector

On the reaction day the stock moved 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.1

15m

-0.8

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7pendingpending+2.0+0.8

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Evonile Pharma Limited said Gagan Sharma, President Specialty Business, will be designated as a senior management person from October 26, 2026. Sharma has over 30 years of pharmaceutical commercial experience and was previously Therapy Area Head for Gene Therapy, Immunology and In-Market Brands at Novartis Healthcare, where he served on the India leadership team.

Likely market impact

This senior leadership appointment has no stated financial impact but may support business execution and growth.